Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal…
Continue Reading-
Ribbon Bio and Syngoi Technologies Commence Strategic Collaboration to Advance Gene Therapies with Synthetic DNA
Ribbon Bio and Syngoi Technologies Commence Strategic Collaboration to Advance Gene Therapies with Synthetic DNA…
Continue Reading -
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of…
Continue Reading -
Neuro Event Labs Oy raises €2.0M investment for commercial expansion in Europe and US market entry of its AI-powered seizure detection device for epilepsy.
Neuro Event Labs Oy raises €2.0M investment for commercial expansion in Europe and US market…
Continue Reading -
Neuro Event Labs, Nelli® officially received European MDR (Medical Device Regulation) certification as a Class IIa medical device
Neuro Event Labs, Nelli® officially received European MDR (Medical Device Regulation) certification as a Class…
Continue Reading -
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001 — Hadean Ventures…
Continue Reading -
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type…
Continue Reading -
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878 — Hadean…
Continue Reading -
Step Pharma announces first patient dosed in a phase 1 trial of dencatistat for patients with solid tumours
Step Pharma announces first patient dosed in a phase 1 trial of dencatistat for patients…
Continue Reading -
Alex Therapeutics has signed an exclusive agreement with Navamedic
Alex Therapeutics has signed an exclusive agreement with Navamedic — Hadean Ventures Home Portfolio Team…
Continue Reading